NYSE:LCI - Lannett Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.78 +0.04 (+0.52 %)
(As of 01/16/2019 01:20 AM ET)
Previous Close$7.74
Today's Range$7.57 - $7.82
52-Week Range$3.33 - $25.02
Volume900,529 shs
Average Volume2.10 million shs
Market Capitalization$305.12 million
P/E Ratio2.51
Dividend YieldN/A
Beta1.94
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages. It also provides its products for various medical indications comprising cholesterol, muscle spasm, pain management, irritable bowel, antipsychosis, gastrointestinal, cardiovascular, thyroid deficiency, central nervous system, urinary, migraine, bronchospasms, and gallstone. In addition, the company manufactures active pharmaceutical ingredients. It markets its products under the Lipitor, Lioresal, Bentyl, Prolixin, MiraLAX, Imdur, Levoxyl/Synthroid, Concerta, Toprol-XL, Prilosec, Ditropan, Protonix, Imitrex, Brethine, and Actigall brands to generic pharmaceutical and private label distributors, drug wholesalers, chain drug retailers, mail-order pharmacies, other pharmaceutical manufacturers, managed care and health maintenance organizations, hospital buying groups, and governmental entities. The company has supply and development agreements with Jerome Stevens Pharmaceuticals, Summit Bioscience LLC, HEC Pharm Group, Andor Pharmaceuticals LLC, Dexcel Pharma, and Aralez Pharmaceuticals. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.

Receive LCI News and Ratings via Email

Sign-up to receive the latest news and ratings for LCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP51601210
Phone215-333-9000

Debt

Current Ratio2.87
Quick Ratio2.07

Price-To-Earnings

Sales & Book Value

Annual Sales$684.56 million
Price / Sales0.45
Cash Flow$4.5765 per share
Price / Cash Flow1.70
Book Value$15.76 per share
Price / Book0.49

Profitability

Net Income$28.69 million
Net Margins-39.74%
Return on Assets7.39%

Miscellaneous

Employees1,251
Market Cap$305.12 million
OptionableOptionable

Lannett (NYSE:LCI) Frequently Asked Questions

What is Lannett's stock symbol?

Lannett trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."

How were Lannett's earnings last quarter?

Lannett Company, Inc. (NYSE:LCI) issued its quarterly earnings results on Wednesday, November, 7th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.05. The firm had revenue of $155.10 million for the quarter, compared to the consensus estimate of $145.79 million. Lannett had a positive return on equity of 21.32% and a negative net margin of 39.74%. The company's revenue for the quarter was up .1% on a year-over-year basis. During the same period in the prior year, the business posted $0.60 earnings per share. View Lannett's Earnings History.

When is Lannett's next earnings date?

Lannett is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Lannett.

What price target have analysts set for LCI?

6 analysts have issued twelve-month target prices for Lannett's stock. Their predictions range from $8.00 to $43.00. On average, they expect Lannett's stock price to reach $24.8750 in the next twelve months. This suggests a possible upside of 219.7% from the stock's current price. View Analyst Price Targets for Lannett.

What is the consensus analysts' recommendation for Lannett?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lannett in the last year. There are currently 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lannett.

Has Lannett been receiving favorable news coverage?

Headlines about LCI stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Lannett earned a news sentiment score of 1.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.

Who are some of Lannett's key competitors?

Who are Lannett's key executives?

Lannett's management team includes the folowing people:
  • Mr. Timothy C. Crew, CEO & Director (Age 57)
  • Mr. Martin P. Galvan, VP of Fin. & CFO (Age 66)
  • Mr. Samuel H. Israel, Gen. Counsel & Chief Legal Officer (Age 56)
  • Mr. John M. Abt, VP & Chief Quality Operations Officer (Age 53)
  • Mr. John Kozlowski, Chief of Staff & Strategy Officer (Age 46)

Who are Lannett's major shareholders?

Lannett's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Louisiana State Employees Retirement System (0.03%) and State of Alaska Department of Revenue (0.03%). Company insiders that own Lannett stock include Albert Paonessa III, Arthur P Bedrosian, David Farber, Kevin Smith, Patrick G Lepore and Timothy C Crew. View Institutional Ownership Trends for Lannett.

Which institutional investors are selling Lannett stock?

LCI stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. View Insider Buying and Selling for Lannett.

Which institutional investors are buying Lannett stock?

LCI stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Lannett stock in the last two years include Albert Paonessa III, Arthur P Bedrosian, Patrick G Lepore and Timothy C Crew. View Insider Buying and Selling for Lannett.

How do I buy shares of Lannett?

Shares of LCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lannett's stock price today?

One share of LCI stock can currently be purchased for approximately $7.78.

How big of a company is Lannett?

Lannett has a market capitalization of $305.12 million and generates $684.56 million in revenue each year. The company earns $28.69 million in net income (profit) each year or $3.10 on an earnings per share basis. Lannett employs 1,251 workers across the globe.

What is Lannett's official website?

The official website for Lannett is http://www.lannett.com.

How can I contact Lannett?

Lannett's mailing address is 9000 STATE ROAD, PHILADELPHIA PA, 19136. The company can be reached via phone at 215-333-9000.


MarketBeat Community Rating for Lannett (NYSE LCI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  401 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  718
MarketBeat's community ratings are surveys of what our community members think about Lannett and other stocks. Vote "Outperform" if you believe LCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel